![]() |
市場調査レポート
商品コード
1618270
経カテーテル僧帽弁修復デバイス:市場洞察・競合環境・市場予測 (~2030年)Transcatheter Mitral Valve Repair Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
||||||
カスタマイズ可能
適宜更新あり
|
経カテーテル僧帽弁修復デバイス:市場洞察・競合環境・市場予測 (~2030年) |
出版日: 2024年12月01日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
|
経カテーテル僧帽弁修復デバイスの市場規模は、2023年の11億9,706万米ドルから、予測期間中は14.95%のCAGRで推移し、2030年には27億5,671万米ドルの規模に成長すると予測されています。
経カテーテル僧帽弁修復デバイスの市場は、循環器疾患、様々な心臓弁疾患を含む心血管障害の有病率の増加、規制クリアランスなどの製品開発活動の増加、座りがちなライフスタイルに関連する障害の増加、低侵襲手術が好まれる傾向の拡大などにより、急速に成長しています。
経カテーテル僧帽弁修復デバイス:市場力学
British Heart Foundation (BHF) によると、ライフスタイルの変化や高齢化などにより、2022年には世界で約6億4,000万人が心臓および循環器疾患を患っていると報告されています。
また、WHOの2020年のデータによると、石灰沈着性大動脈弁狭窄症の有病率は世界で900万人と推計されています。循環器疾患や様々な心臓弁疾患を含む心血管疾患の有病率の増加は、経カテーテル僧帽弁修復デバイスの需要を増加させると考えられています。
低侵襲手術に対する患者の嗜好の高まりも、予測期間中の市場成長に良い結果をもたらすと思われます。経カテーテル僧帽弁修復デバイスは、回復時間の短縮、術後の痛みの軽減、入院期間の短縮、創合併症の軽減、より優れた創プロテーゼなどの低侵襲アプローチにより、従来の手術と比較して利点を提供します。
タイプ別では、生体弁の部門が2023年に大きな収益シェアを占めると予想されています。これは、材料科学の進歩、耐久性の向上、臨床応用の拡大によるものです。
ブタやウシの組織に由来する生体弁は、優れた血行力学的性能、血栓原性の低減、生涯抗凝固療法を必要としないことから、ますます好まれるようになっており、高齢者や活動的な患者には特に有利です。
当レポートでは、世界の経カテーテル僧帽弁修復デバイスの市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。
Transcatheter Mitral Valve Repair Devices Market by Type (Mechanical Valve and Bioprosthetic Tissue (Biological) Valve), Indication (Mitral Valve Regurgitation, Mitral Valve Stenosis, and Others), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the growing prevalence of cardiovascular disorders and the increasing product developmental activities worldwide
The transcatheter mitral valve repair devices market was valued at USD 1,197.06 million in 2023, growing at a CAGR of 14.95% during the forecast period from 2024 to 2030 to reach USD 2,756.71 million by 2030. The transcatheter mitral valve repair devices market is expanding rapidly due to the growing prevalence of cardiovascular disorders including circulatory diseases, various heart valve diseases, increasing product developmental activities such as regulatory clearances, rising sedentary lifestyle & lifestyle-associated disorders, increasing preference for minimally invasive surgeries that are expected to escalate the overall growth of the transcatheter mitral valve repair devices market during the forecast period from 2024 to 2030.
Transcatheter Mitral Valve Repair Devices Market Dynamics:
According to the British Heart Foundation (BHF), it was reported in 2024, that around 640 million people in 2022 were living with heart and circulatory diseases worldwide owing to changing lifestyles, aging, and a growing population.
As per data from the World Health Organization (WHO) 2020, the prevalence of calcific aortic valve stenosis was 9 million across the world. Thus, the increasing prevalence of cardiovascular diseases including circulatory diseases and various heart valve diseases will increase the demand for transcatheter mitral valve repair devices.
The increasing patient preference for minimally invasive surgeries is also likely to bode well for the market growth during the forecast period. Transcatheter mitral valve repair devices offer advantages over conventional surgeries owing to their minimally invasive approach, such as shorter recovery time, less post-operational pain, less stay at the hospital, fewer wound complications, and better wound prosthesis.
Additionally, in January 2021, Cardiovascular Systems, Inc. received CE Mark for Diamondback 360(R) Coronary Orbital Atherectomy System.
Therefore, the factors stated above collectively will drive the overall transcatheter mitral valve repair devices market growth.
However, risk and complications associated with transcatheter mitral valve repair procedures, stringent regulatory approval process, among others may prove to be challenging factors for transcatheter mitral valve repair devices market growth.
Transcatheter Mitral Valve Repair Devices Market Segment Analysis:
Transcatheter Mitral Valve Repair Devices Market by Type (Mechanical Valve and Bioprosthetic Tissue (Biological) Valve), Indication (Mitral Valve Regurgitation, Mitral Valve Stenosis, and Others), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the type segment of the transcatheter mitral valve repair devices market, the bioprosthetic tissue (biological) valve category is expected to have a significant revenue share in the year 2023. This is due to the advancements in material science, enhanced durability, and expanding clinical applications.
Bioprosthetic valves, derived from porcine or bovine tissue, are increasingly preferred for their superior hemodynamic performance, reduced thrombogenicity, and elimination of lifelong anticoagulation therapy, which is particularly advantageous for elderly and active patients.
Further, the increasing product launches & approvals and other strategic activities will in turn propel the demand for bioprosthetic tissue valve devices. For instance, in September 2021, Abbott received US FDA approval for Epic Plus and Epic Plus Supra Stented Tissue Valves to improve therapy options for people suffering from aortic or mitral valve disease. Epic Plus, a bioprosthetic valve, do not require long-term use of blood-thinner medication, making them the recommended option for people, especially aged over 70 years who are at risk of taking blood thinners.
Therefore the widespread uses and various features of bioprosthetic tissue (biological) valve) enhance performance and usability, solidifying the significant impact on the growth of the overall transcatheter mitral valve repair devices market during the forecast period from 2024 to 2030.
North America is expected to dominate the overall transcatheter mitral valve repair devices market:
Among all the regions, North America is expected to dominate the transcatheter mitral valve repair devices market in the year 2023 and is expected to do the same during the forecast period. This can be attributed to several factors including the high instances of myocardial infarction, heart valve diseases, and their associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the transcatheter mitral valve repair devices market in the North America region during the forecast period from 2024 to 2030.
Disease Control and Prevention (CDC) (2024), it was stated that 805,000 people in the US have a myocardial infarction (heart attack) every year on average. Furthermore, as per the same source, it was stated that heart disease is an umbrella term that encompasses numerous indications. Some of the key risk factors associated with heart disease are high blood cholesterol, high blood pressure, and smoking. The source further mentioned that about half of Americans (47%) have at least one of these three risk factors.
According to the Canadian Cardiovascular Society (2022), it was reported that in 2022, 2.5% of the population had heart valve diseases, which is increasing significantly after the age of 65, reaching up to 13% after the age of 75. It was also estimated by the same source that in 2040, Canada will have an estimated 1.5 million people over 65 years with heart valve disease.
Since cardiovascular disorders are rising in the region among middle-aged individuals, the demand for more effective diagnostic and treatment options is increasing significantly. This trend is fueling investment in innovative technologies and expanding the market for transcatheter mitral valve repair devices.
Rising product developmental activities by regulatory bodies and key players in the region will further boost the market for transcatheter mitral valve repair devices. For example, in September 2022, Edwards Lifesciences received FDA approval for its Pascal Precision system. The device used minimally invasive surgery to repair the mitral valve in patients with degenerative mitral regurgitation, a condition where the valve between heart chambers does not close completely, allowing blood to leak back through.
Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North American transcatheter mitral valve repair devices market.
Transcatheter Mitral Valve Repair Devices Market key players:
Some of the key market players operating in the transcatheter mitral valve repair devices market include Abbott, Edwards Lifesciences Corporation, Shockwave Medical, Inc., LivaNova PLC, NeoChord, Inc., Coramaze Technologies, CryoLife, Inc., JenaValve Technology, Inc., Medtronic, Boston Scientific Corporation, and others.
Recent Developmental Activities in the Transcatheter Mitral Valve Repair Devices Market:
Key Takeaways from the Transcatheter Mitral Valve Repair Devices Market Report Study
Target Audience who can be benefited from this Transcatheter Mitral Valve Repair Devices Market Report Study
Frequently Asked Questions for the Transcatheter Mitral Valve Repair Devices Market: